Market Measurement | China Chemiluminescence Immunoassay Analyzer Market Measurement Report
01． Product brief introduction
-
Product category
According to the 2017 Classification Catalog of Medical Devices issued by the CFDA, the chemiluminescent immunoassay analyzer belongs to the 22nd category of clinical testing devices, and the management category is II.
02. Development drivers
-
Policy factor
Since the “Fourteenth Five-Year Plan”, the National Health Commission and the National Development and Reform Commission have issued relevant policies and regulations many times, listing diagnostic and testing equipment as the key development area, and vigorously developing chemiluminescence immunodiagnosis.
-
Social and economic factors
After the outbreak of the novel coronavirus, China’s in vitro diagnosis industry has developed rapidly. By the end of 2022, there were 55 listed companies in vitro diagnosis in China, 29 of which were listed during the epidemic period. With the support of capital, domestic companies have broken through the technical barriers and many products have been approved for listing, among which chemiluminescence immunodiagnosis is still one of the most popular in this field.
-
Technical factors
Immunodiagnosis has an early start, mature development, low detection cost, and occupies the largest market share in the whole field of in vitro diagnosis. Immunodiagnosis has an early start, mature development, low detection cost, and occupies the largest market share in the whole field of in vitro diagnosis. The main methods of immunodiagnosis include radioimmunization, colloidal gold, enzyme-linked immunization and chemiluminescence immunization, among which radioimmunization has been basically phased out due to expensive consumables and radioactive contamination, colloidal gold and enzyme-linked immunization have low detection sensitivity, and have been gradually replaced by chemiluminescence immunization with fast detection speed and high sensitivity. With the development of chemiluminescence immunization technology, the cost is further reduced. It is expected to continue to expand its proportion in the field of immunodiagnosis.
03．Market size
-
Calculation logic
There are many enterprises in the chemiluminescence immunoanalyzer market in China, and the main participants include Siemens, Roche, Abbott, Danaher, Snibe, Antubio, YHLO and other enterprises.
Revenue of disassembling enterprises: disassembling revenue of listed enterprises through public data. Taking Roche as an example, through disassembling revenue: obtaining the proportion of immunological diagnosis business in POC and Core Lab business, the proportion of POC and Core Lab business in Asia-Pacific region, and the proportion of business in China in Asia-Pacific region; The revenue of Roche’s chemiluminescence immunoassay analyzer in China was finally obtained by combining the proportion of data resolution instruments and reagents of Joinchain MDCloud and the proportion of chemiluminescence immunoassay analyzer in all immunoassay analyzers.
The result of integration calculation: The results of integrated calculation are as follows: After disintegrating the revenue of all enterprises, the market concentration and the proportion of each enterprise in this field are analyzed by using the MDCloud bidding data, and the market size of chemiluminescence immunoanalyzer was obtained by synthesizing the above results.
-
Data basis
(1) Bidding data
The data range is the open bid-winning data of various medical institutions, scientific research institutions, testing institutions, universities and other institutions from 2019 to 2021; The data includes bid-winning time, bid-winning quantity, bid-winning price, bid-winning brand, bid-winning model, bid-winning unit, etc.
(2) Report of listed enterprises
It mainly includes the listing quarterly report, annual report, prospectus and other materials of major enterprises in this field.
-
Market size forecast
After calculating the market size of chemiluminescence immunoanalyzer from 2019 to 2021, we assume that the market size of chemiluminescence immunoanalyzer in China will continue to maintain stable and rapid growth in the next four years, and forecast that the market size of chemiluminescence immunoanalyzer in China will reach 11.625 billion yuan in 2025.
04. Market pattern
It is estimated that CR4 in China’s chemiluminescence immunoanalyzer field is 61.6% in 2021, among which the share of domestic brands is less than 40%. With the acceleration of domestic substitution for imports, the share of domestic brands is increasing year by year, and the market pattern of China’s chemiluminescence immunoanalyzer field is about to be reshaped.
China is encouraging China end uses for more domestic products in latest years. Thus, more and more overseas manufacturers are planning localization in China. BradyKnows localization team has extensive experiences in facility establishment, audit, supplier evaluation, manufacturing, registration, and marketing in China. Pls feel free to let us know any questions on China entry via info@bradyknowsmedical.com
Source：Joinchain Medical Device
Translated & edited by Bradyknows
